Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other financing activities (2016 - 2025)

Adma Biologics' Other financing activities history spans 8 years, with the latest figure at -$2.2 million for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to -$2.2 million; the TTM value through Dec 2025 reached $127000.0, down 94.6%, while the annual FY2023 figure was $2.4 million, 15.52% down from the prior year.
  • Other financing activities reached -$2.2 million in Q4 2025 per ADMA's latest filing, down from $2.4 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.4 million in Q1 2022 to a low of -$2.2 million in Q4 2025.
  • Average Other financing activities over 3 years is $582000.0, with a median of $404562.0 recorded in 2022.
  • The largest YoY upside for Other financing activities was 3265177.78% in 2023 against a maximum downside of 3265177.78% in 2023.
  • A 3-year view of Other financing activities shows it stood at $72.0 in 2022, then skyrocketed by 3265177.78% to $2.4 million in 2023, then plummeted by 194.6% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Other financing activities are -$2.2 million (Q4 2025), $2.4 million (Q4 2023), and $72.0 (Q4 2022).